SGLT2 inhibitors

Abstract

The SGLT2 inhibitors offer a new therapeutic approach to reducing blood glucose levels in patients with type 2 diabetes by working at the level of the kidney.1, 2, 3 • SGLT2 inhibitors, given their insulin-independent mechanism of action, are associated with very low rates of hypoglycaemia in clinical studies.1 • Beyond improving glucose control, SGLT2 inhibitors offer potential benefits by reducing body weight and blood pressure.6, 15 • SGLT2 inhibitors are usually recommended as add-on therapy, e.g. to metformin, or another glucose-lowering agent.15 # EMC = electronic medicines compendium (UK).